Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
Portfolio Pulse from
Plus Therapeutics has partnered with SpectronRx to manufacture Rhenium (186Re) Obisbemeda, a radiotherapy for CNS cancers. This agreement supports Plus Therapeutics' preparation for late-stage clinical trials and commercial demand.
November 06, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Plus Therapeutics has signed a Manufacturing Services Agreement with SpectronRx to produce Rhenium (186Re) Obisbemeda, a radiotherapy for CNS cancers. This partnership is crucial for their upcoming late-stage clinical trials and commercial readiness.
The partnership with SpectronRx is a strategic move for Plus Therapeutics as it prepares for late-stage clinical trials and commercial demand. This could positively impact PSTV's stock as it shows progress in their product pipeline and readiness for market entry.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90